90 related articles for article (PubMed ID: 23416779)
1. Nanotechnology-based strategies for the diagnosis and treatment of intracranial neoplasms.
Horowitz PM; Chiocca EA
World Neurosurg; 2013; 80(1-2):53-5. PubMed ID: 23416779
[No Abstract] [Full Text] [Related]
2. Targeted cell uptake of a noninternalizing antibody through conjugation to iron oxide nanoparticles in primary central nervous system lymphoma.
Wang T; Kievit FM; Veiseh O; Arami H; Stephen ZR; Fang C; Liu Y; Ellenbogen RG; Zhang M
World Neurosurg; 2013; 80(1-2):134-41. PubMed ID: 23298674
[TBL] [Abstract][Full Text] [Related]
3. Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma.
Saesoo S; Sathornsumetee S; Anekwiang P; Treetidnipa C; Thuwajit P; Bunthot S; Maneeprakorn W; Maurizi L; Hofmann H; Rungsardthong RU; Saengkrit N
Colloids Surf B Biointerfaces; 2018 Jan; 161():497-507. PubMed ID: 29128836
[TBL] [Abstract][Full Text] [Related]
4. Nanomedicine Applications in Treatment of Primary Central Nervous System Lymphoma: Current State of the Art.
Wang M; Qu Y; Hu D; Niu T; Qian Z
J Biomed Nanotechnol; 2021 Aug; 17(8):1459-1485. PubMed ID: 34544527
[TBL] [Abstract][Full Text] [Related]
5. Engineering GVL through T cell gene transfer.
Jensen MC
Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):5. PubMed ID: 18162214
[No Abstract] [Full Text] [Related]
6. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells.
Hayden-Ledbetter MS; Cerveny CG; Espling E; Brady WA; Grosmaire LS; Tan P; Bader R; Slater S; Nilsson CA; Barone DS; Simon A; Bradley C; Thompson PA; Wahl AF; Ledbetter JA
Clin Cancer Res; 2009 Apr; 15(8):2739-46. PubMed ID: 19351771
[TBL] [Abstract][Full Text] [Related]
7. Primary central nervous system lymphoma: current state of anti-CD20 therapy and appraisal of reported response criteria.
Siegal T
J Clin Neurosci; 2014 May; 21(5):709-15. PubMed ID: 24725453
[TBL] [Abstract][Full Text] [Related]
8. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
[TBL] [Abstract][Full Text] [Related]
9. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy.
Jensen MC; Cooper LJ; Wu AM; Forman SJ; Raubitschek A
Cytotherapy; 2003; 5(2):131-8. PubMed ID: 12745575
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD20-based therapy of B cell lymphoma: state of the art.
Kosmas C; Stamatopoulos K; Stavroyianni N; Tsavaris N; Papadaki T
Leukemia; 2002 Oct; 16(10):2004-15. PubMed ID: 12357351
[TBL] [Abstract][Full Text] [Related]
12. Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma.
Antonini G; Cox MC; Montefusco E; Ferrari A; Conte E; Morino S; Latino P; Trasimeni G; Monarca B
J Neurooncol; 2007 Jan; 81(2):197-9. PubMed ID: 16937012
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human B-cell lymphoma by an anti-CD20 antibody and its chimeric F(ab')2 fragment via induction of apoptosis.
Liu Y; Zheng M; Lai Z; Xiong D; Fan D; Xu Y; Peng H; Shao X; Xu Y; Yang M; Wang J; Liu H; Xie Y; Yang C; Zhu Z
Cancer Lett; 2004 Mar; 205(2):143-53. PubMed ID: 15036646
[TBL] [Abstract][Full Text] [Related]
14. Correspondence re: T. Davis et al., therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res., 5: 611-615, 1999.
Grillo-López AJ; Kunkel L
Clin Cancer Res; 2000 Jan; 6(1):317-8. PubMed ID: 10656464
[No Abstract] [Full Text] [Related]
15. [Monoclonal anti-CD20 antibody therapy].
Juhel L; Solal-Celigny P
Rev Prat; 2004 Apr; 54(7):711-2. PubMed ID: 15253285
[No Abstract] [Full Text] [Related]
16. [Primary central nervous system lymphoma: report of one case].
Zhao P; Su RG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Apr; 10(2):175-6. PubMed ID: 12513826
[TBL] [Abstract][Full Text] [Related]
17. Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma.
Chen F; Fan C; Gu X; Zhang H; Liu Q; Gao X; Lu J; He B; Lai X
Med Sci Monit; 2015 Jul; 21():2110-5. PubMed ID: 26195067
[TBL] [Abstract][Full Text] [Related]
18. Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease.
Ambady P; Fu R; Netto JP; Kersch C; Firkins J; Doolittle ND; Neuwelt EA
Fluids Barriers CNS; 2017 Jun; 14(1):16. PubMed ID: 28577579
[TBL] [Abstract][Full Text] [Related]
19. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.
Demidem A; Lam T; Alas S; Hariharan K; Hanna N; Bonavida B
Cancer Biother Radiopharm; 1997 Jun; 12(3):177-86. PubMed ID: 10851464
[TBL] [Abstract][Full Text] [Related]
20. [CD20].
Terui Y
Nihon Rinsho; 2012 Nov; 70 Suppl 8():170-5. PubMed ID: 23513833
[No Abstract] [Full Text] [Related]
[Next] [New Search]
